story of the week
Overall Survival With First-Line Atezolizumab Plus Vemurafenib and Cobimetinib in BRAFV600-Positive Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Lancet Oncol 2022 Nov 29;[EPub Ahead of Print], PA Ascierto, D Stroyakovskiy, H Gogas, C Robert, K Lewis, S Protsenko, RP Pereira, T Eigentler, P Rutkowski, L Demidov, N Zhukova, J Schachter, Y Yan, I Caro, C Hertig, C Xue, L Kusters, GA McArthur, R GutzmerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.